Beyond Air's Q2 net loss narrows slightly
XAIR•XAIR•XAIR•XAIR•Beyond Air reported record Q2 revenue of $2.32 million, up 28% year over year, and a net loss of $7.82 million, slightly lower than a year earlier. It reaffirmed revenue guidance of $8 million for 2026 and $16 million to $18 million for 2027, pending FDA approval of its second-generation LungFit PH.
Beyond Air's Q2 revenue rose 28% year over year to a record $2.32 million. The company posted a net loss of $7.82 million, slightly lower than last year, and gross profit of $197,000.
The company reaffirmed its revenue guidance of $8 million for calendar 2026, excluding the second-generation LungFit PH, and $16 million to $18 million for calendar 2027, pending FDA approval. Beyond Air expects the FDA review of the system to conclude after audit readiness in mid-December.
Beyond Air said continued adoption of the first-generation LungFit PH and an enhanced commercial strategy supported revenue growth. It cited new account wins and renewals as evidence of customer satisfaction.
